VPC-14449 is a specific inhibitor of AR-DBD. It acts by inhibiting both Y594A and Q592A mutants, blocking the interaction of the AR with androgen response elements in the nucleus.. References: Dalal K, Roshan-Moniri M, Sharma A, Li H, Ban F, Hassona MD, Hsing M, Singh K, LeBlanc E, Dehm S, Tomlinson Guns ES, Cherkasov A, Rennie PS. Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer. J Biol Chem. 2014 Sep 19;289(38):26417-29. doi: 10.1074/jbc.M114.553818. Epub 2014 Aug 1. Erratum in: J Biol Chem. 2015 Oct 23;290(43):25850. J Biol Chem. 2014 Dec 5;289(49):33877. Hessein, Mohamed [Corrected to Hassona, Mohamed D]. J Biol Chem. 2017 Mar 10;292(10 ):4359. PubMed PMID: 25086042; PubMed Central PMCID: PMC4176249.

纯度：≥98%

CAS：1621375-32-3